Evaluation of automated airway morphological quantification for assessing fibrosing lung disease

TL;DR

This study introduces AirQuant, an automated pipeline for quantifying airway abnormalities in CT scans, which correlates with IPF severity and could serve as a novel imaging biomarker.

Contribution

AirQuant is a new open-source tool that improves airway skeletonisation accuracy and provides clinically interpretable measures for assessing IPF.

Findings

Reduced airway intertapering in IPF patients

Increased airway tortuosity in IPF patients

Most marked differences in lower lung lobes

Abstract

Abnormal airway dilatation, termed traction bronchiectasis, is a typical feature of idiopathic pulmonary fibrosis (IPF). Volumetric computed tomography (CT) imaging captures the loss of normal airway tapering in IPF. We postulated that automated quantification of airway abnormalities could provide estimates of IPF disease extent and severity. We propose AirQuant, an automated computational pipeline that systematically parcellates the airway tree into its lobes and generational branches from a deep learning based airway segmentation, deriving airway structural measures from chest CT. Importantly, AirQuant prevents the occurrence of spurious airway branches by thick wave propagation and removes loops in the airway-tree by graph search, overcoming limitations of existing airway skeletonisation algorithms. Tapering between airway segments (intertapering) and airway tortuosity computed by AirQuant were compared between 14 healthy participants and 14 IPF patients. Airway intertapering was significantly reduced in IPF patients, and airway tortuosity was significantly increased when compared to healthy controls. Differences were most marked in the lower lobes, conforming to the typical distribution of IPF-related damage. AirQuant is an open-source pipeline that avoids limitations of existing airway quantification algorithms and has clinical interpretability. Automated airway measurements may have potential as novel imaging biomarkers of IPF severity and disease extent.